Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada
16/12/2024 21:41
Dec 16 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES FILING OF NEW DRUG
SUBMISSION FOR
QELBREE® (VILOXAZINE) IN CANADA
Source text: ID:nGNX2J7l3P
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing